The results of these experimental tests are discussed in the paper with emphasis on the correlation between the roughness of the surface and the outcomes of both shear and pull-out tests; this information can be used in design in order to prescribe the minimum roughness level necessary to attain the expected debonding strength of the reinforcement.
In regular ELISA group, the strain used to extract antigens for the test was not specified in 68 (58.2%), and in all the commercial tests this information was not available; in 59 (50.7%) tests the T. cruzi life cycle form used as sources of antigens was not specified, and in 65 (56.0%) antigen purification was not specified or not clear in the report.
These vast data were used to identify SSR motifs specific for the tested chromosome arms or whole chromosomes and we tested this information by their physical localization on metaphase chromosomes.
The ethnicity of the individual tested should be included if relevant for the purpose of testing; this information may be useful to select the most appropriate test methods and to calculate residual risks.
For Bacillus species isolates, we contacted laboratories by phone to gather information about motility and hemolysis tests when this information was not provided on the report.
The performance specification derived from the validation should be used to assess the 'validity' of each test run and this information should be added to the validation file at appropriate intervals.
For example, if a family member is known to have a specific mutation that is not on most standard testing panels this information will allow a healthcare provider to order the proper test on a (yet) unaffected relative and avoid a false negative result.
The study does not test whether this information was useful enough to allow investors to make sufficient profit trading on it to justify the extra risk.
Preemptive testing, embedding this information into the EMR with appropriate decision support, and then seamlessly presenting it at the point of care when needed, rather than requiring tests to be ordered each time a relevant medication is prescribed, could help to minimize delay, cost, lack of follow-through, and duplicate testing.
If there is sufficient evidence (defined with the same quality metrics as above) to determine that the given individual does not have an alternative allele at the tested location, this information is stored in the database as a "SARA" (Same As Reference Assembly) position, which can be thought of as a computational genotyping assay.
If a wide range of genetic information is stored in an EMR, including results from multiplex tests, some of this information will not be immediately relevant to the patient's health care.
